Items Tagged ‘overall survival’

October 24th, 2016

Yervoy® Improves Overall Survival in Fully Resected Stage III Melanoma Patients


Results were presented during the 2016 European Society for Medical Oncology Congress demonstrating that Yervoy® (ipilimumab) compared to placebo improves survival in stage III melanoma patients who are at high risk of recurrence following complete surgical resection. In the study, Yervoy compared with placebo significantly improved overall survival (OS) with five-year OS rates at 65.4% […]

View full entry

Tags: 2016, advanced melanoma, ESMO, high-risk, ipilimumab, Melanoma, News, overall survival, stage III, Stage III Melanoma, Yervoy